JBIO - Jade Biosciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$37.75
DETAILS
HIGH:
$45.00
LOW:
$32.00
MEDIAN:
$37.00
CONSENSUS:
$37.75
UPSIDE:
69.97%
About Jade Biosciences, Inc. (https://jadebiosciences.com)
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Tom Frohlich | President, CEO & Director | 1976 | $1,019,883 USD |
| Andrew James King | President of Research & Development | 1980 | $765,901 USD |
| Bradford D. Dahms | CFO & Treasurer | 1989 | $350,051 USD |
| Amy Sullivan | Senior Vice President of Development Operations | – | – |
| Edward R. Conner | Chief Medical Officer | 1973 | – |
| Elizabeth Balta | Chief Legal Officer & Corporate Secretary | 1971 | – |
| Jason Wright | Senior Vice President of Chemistry, Manufacturing & Controls | – | – |
| Jonathan Quick | Senior Vice President of Finance | – | – |
| Lori Stewart | Senior Vice President of People | – | – |
| Sandy Lewis | Senior Vice President, Biometrics & Clinical Strategy | – | – |
| Valerie Fauvelle | Senior Vice President of Regulatory & Quality | – | – |